Name

Alphamab Oncology

Legal name

江苏康宁杰瑞生物制药有限公司

Website

https://alphamabonc.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Oncology Specialty Pharmaceuticals (HLAIACAA), Breast Oncology (HLAKAFAJ)

Keywords

• Oncology biopharmaceuticals
• Bispecific antibodies
• Antibody-drug conjugates
• Subcutaneous antibody formulations
• Immuno-oncology therapeutics

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of approved biopharmaceutical products including KN035 (envafolimab), China's first approved subcutaneously administered PD-L1 inhibitor. The company derives the majority of its revenue from product sales in the Chinese pharmaceutical market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Alphamab Oncology discovers, develops, manufactures, and commercializes innovative oncology biopharmaceuticals built on proprietary bispecific antibody and antibody-drug conjugate (ADC) platforms. Its commercial portfolio includes KN035 (Envafolimab), the world's first subcutaneously administered PD-L1 inhibitor, and KN026 (Anbenitamab), China's first domestically developed HER2 bispecific antibody, alongside a clinical pipeline of biparatopic and bispecific ADCs and fusion proteins for solid tumors.

Product overview

Alphamab Oncology is a biopharmaceutical company focused on oncology drug development. The company has developed a portfolio of innovative biologics including: (1) Two approved products - Envarki® (KN035/Envafolimab, the world's first subcutaneous PD-L1 inhibitor) and Enitu® (KN026/Anbenitamab, China's first domestically developed HER2 bispecific antibody); (2) A pipeline of bispecific antibodies and antibody-drug conjugates (ADCs) including JSKN003 (biparatopic HER2 ADC), JSKN016 (TROP2/HER3 bispecific ADC), JSKN021 (EGFR/HER3 dual payload ADC), JSKN022 (PD-L1/αvβ6 bispecific ADC), JSKN027 (PD-L1/VEGFR2 bispecific ADC), and JSKN033 (subcutaneous ADC formulation); and (3) KN046 (PD-L1/CTLA-4 bispecific antibody) and KN019 (B7-CTLA4 fusion protein). The company leverages multiple proprietary technology platforms including glycan site-specific conjugation, linker-payload, dual-payload ADC, bispecific antibody (CRIB platform), high-concentration subcutaneous formulation, and single-domain antibody platforms.

Differentiator

Problem solved

Functional benefit

Brands

• 恩维达®: Brand name for KN035 (envafolimab), the globally first subcutaneous PD-L1 inhibitor.
• 恩尼妥®

Products and services

• KN035 (Envafolimab) / Envarki (恩维达) A single-domain antibody PD-L1 inhibitor providing convenient subcutaneous injection administration for cancer treatment, offering improved patient compliance compared with intravenous infusion. Approved for use in patients with solid tumors including gastric cancer and other PD-L1 expressing malignancies.
• KN026 (Anbenitamab) / Enitu (恩尼妥) China's first domestically developed HER2 bispecific antibody using the CRIB platform technology to simultaneously bind two non-overlapping epitopes of the HER2 receptor (domain IV and domain II), blocking HER2 signaling and inducing receptor aggregation for enhanced ADCC and CDC effects. Indicated for HER2-positive gastric cancer and being developed for HER2-positive breast cancer.
• JSKN003 Biparatopic HER2-targeting antibody-drug conjugate (ADC) using the company's glycan site-specific conjugation platform to deliver cytotoxic payloads to HER2-positive tumor cells. Has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from Chinese and US authorities for platinum-resistant ovarian cancer and HER2-positive colorectal cancer.
• JSKN016 TROP2/HER3 bispecific antibody-drug conjugate targeting TROP2 and HER3 receptors, in clinical development for triple-negative breast cancer (TNBC) and other solid tumors. Phase III clinical trial initiated in March 2026.
• JSKN021 EGFR/HER3 dual payload bispecific ADC, the company's first dual-payload ADC to enter clinical stage, combining EGFR and HER3 targeting with dual payload delivery technology. IND application accepted by China's CDE in March 2026.
• JSKN022 PD-L1/αvβ6 bispecific antibody-drug conjugate, described as the world's first PD-L1/αvβ6 bispecific ADC to enter clinical stage, in development for advanced malignant solid tumors. Phase I initiated October 2025.
• JSKN027 PD-L1/VEGFR2 bispecific antibody-drug conjugate for advanced malignant solid tumors, combining PD-L1 targeting with VEGFR2 inhibition. IND application accepted by China's CDE.
• JSKN033 Subcutaneous injection formulation combining JSKN003 and envafolimab (KN035) for subcutaneous administration of HER2-targeting ADC therapy, leveraging the company's high-concentration subcutaneous formulation platform.
• KN046 PD-L1/CTLA-4 bispecific antibody with a proprietary design combining CTLA-4 and PD-L1 single-domain antibodies, targeting PD-L1 high-expressing tumor microenvironments and clearing immunosuppressive Treg cells. Has received FDA Orphan Drug Designation for thymic epithelial tumors.
• KN019 B7-CTLA4 dual-targeting fusion protein for autoimmune and cancer applications.

Quantifiable outcome

• China's first approved subcutaneously administered PD-L1 inhibitor
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• 思路迪医药 (3D Medicines)coreStrategic or Co-development PartnerLicensing agreement for KN035 (envafolimab) with 3D Medicines (思路迪医药). Under this partnership, Alphamab Oncology granted rights to 3D Medicines for the development and commercialization of KN035, China's first subcutaneously administered PD-L1 inhibitor, in specified territories.
• 石药集团/上海津曼特 (CSPC Pharmaceutical Group / Shanghai Jinmant Biotechnology)coreStrategic or Co-development PartnerCo-development partnership for KN026, a bispecific antibody candidate. Alphamab Oncology collaborates with Shanghai Jinmant Biotechnology (under CSPC Pharmaceutical Group) for the joint development of KN026 for the treatment of HER2-positive solid tumors.
• ArriVentminorStrategic or Co-development PartnerStrategic partnership with ArriVent for the development and potential commercialization of innovative biopharmaceutical candidates in specified territories.
• GlenmarkminorStrategic or Co-development PartnerPartnership with Glenmark for the development and commercialization of selected biopharmaceutical products in defined markets.
• SanoficoreStrategic or Co-development PartnerClinical trial collaboration with Sanofi for KN026 in combination with Taxotere (docetaxel). This partnership involves clinical development activities exploring the combination of KN026 with Sanofi products for the treatment of HER2-positive solid tumors.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• AstraZeneca: Global oncology major co-developing Enhertu (HER2 ADC) with Daiichi Sankyo and Imfinzi (durvalumab, PD-L1). Comparable as a broad incumbent in PD-L1 and HER2 ADC — both competitive and a potential partner for Alphamab assets.
• Roche: Pioneer in HER2-targeted therapy (Herceptin/trastuzumab, Perjeta/pertuzumab, Kadcyla/T-DM1 ADC). Closest established incumbent reference for KN026's HER2 bispecific positioning against standard-of-care.
• Daiichi Sankyo: Global leader in HER2 ADC development (trastuzumab deruxtecan/Enhertu, partnered with AstraZeneca) and a broader oncology franchise. Comparable as the dominant player in Alphamab's most-contested indication (HER2 ADCs).

Direct peers

• RemeGen: Hong Kong-listed (9995.HK) Chinese biopharma with a HER2-targeted ADC (disitamab vedotin, 爱地希®) that directly competes with Alphamab's JSKN003 in HER2-positive oncology. Closest direct therapeutic area competitor.
• BeiGene: Hong Kong-/US-listed (6160.HK / ONC) Chinese oncology biotech with commercial-stage Brukinsa and tislelizumab. Comparable as a globally active, China-rooted oncology biopharma with multiple commercial products and an extensive pipeline.
• Innovent Biologics: Hong Kong-listed (1801.HK) Chinese biopharma with PD-1 leader (sintilimab) and a growing bispecific antibody pipeline. Directly comparable business model: Chinese-anchored oncology biologics developer with commercial-stage products and pipeline.
• Akeso (Akeso Inc.): Hong Kong-listed (9926.HK) Chinese biopharma and a leading domestic bispecific antibody developer (e.g., PD-1/VEGF cadonilimab). Highly comparable to Alphamab in bispecific antibody platform focus, oncology pipeline, and Chinese commercialization model.
• Hansoh Pharmaceutical: Hong Kong-listed (3692.HK) Chinese pharma with a strong oncology biologics franchise. Comparable as a Chinese oncology-focused biopharma with commercialization infrastructure and pipeline depth.

Emerging players

• Duality Biologics: Emerging Chinese biotech focused on next-generation ADCs with multiple partnership deals (e.g., BMS). Comparable as an early-stage ADC specialist with a complementary technology focus in oncology.

Others

• CSPC Pharmaceutical Group: Hong Kong-listed (1093.HK) Chinese pharma conglomerate that is Alphamab's strategic partner for JSKN003 in mainland China (RMB 3.08B deal). Relevant as both an incumbent Chinese pharma and a counterparty whose commercial execution drives Alphamab's near-term royalty/milestone economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alphamab Oncology